Regulatory FDA Approves First New Molecular Entity Under National Priority Voucher Program FDAThe U.S.RegulatoryRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) FDA The U.S. RegulatoryRead full story Post navigation Previous: Ambrosia adds a megaround for obesity drugsNext: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
